NCT07033208 Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance
| NCT ID | NCT07033208 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Crohn Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2025-06-03 |
| Primary Completion | 2027-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2025-06-03 with a primary completion date of 2027-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this research is to learn how a new device called the wireless thermal capsule (WTC) can collect thermal data to help see diseases that happen in the gastrointestinal (GI) tract, such as Crohn's Disease.
Eligibility Criteria
Inclusion Criteria: * Participant is 18 -75 years old * Participant is considered healthy, with no known illnesses * Participant can follow fasting requirements * Participant can follow bowel prep instructions * Participant can provide informed consent Exclusion Criteria: * Participant is older than 75 years of age * Participant with current dysphagia or any swallowing disorder * Participant with any current condition believed to have an increased risk of capsule retention such as gastrointestinal strictures, intestinal tumors, bowel obstruction, incomplete colonoscopies or fistula * Participant with a diagnosis of gastroparesis or small bowel or large bowel dysmotility * Participant with a history of inflammatory bowel disease (IBD), intestinal Crohn's disease, chronic constipation, or rectal bleeding * Participant with clinical evidence of renal disease, including clinically significant laboratory abnormalities of renal function within the past 6 months * Participant with chronic usage of nonsteroidal anti-inflammatory drugs (NSAIDs) * Participants with a known contradiction to metoclopramide * Participants with a known contraindication to polyethylene glycol * Participant with currently suspected or diagnosed with hematochezia, melena, iron deficiency with or without anemia * Participant who has had intestinal surgery in the past * Participant with a history of congestive heart failure * Participant with Type I or Type II Diabetes * Participant has a cardiac pacemaker or other implanted electromedical device. * Participant expected to undergo MRI examination within 7 days after ingestion of the capsule. * Participant has participated in an investigational drug or device research study within 30 days of enrollment that may interfere with the subject's safety or ability to participate in this study * Participant with delayed gastric emptying * Participant who is pregnant, suspected pregnant, or is actively breast-feeding.
Contact & Investigator
Guillermo Tearney, MD, PhD
PRINCIPAL INVESTIGATOR
Massachusetts General Hospital
Frequently Asked Questions
Who can join the NCT07033208 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Crohn Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07033208 currently recruiting?
Yes, NCT07033208 is actively recruiting participants. Contact the research team at tearneylabtrials@partners.org for enrollment information.
Where is the NCT07033208 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT07033208 clinical trial?
NCT07033208 is sponsored by Massachusetts General Hospital. The principal investigator is Guillermo Tearney, MD, PhD at Massachusetts General Hospital. The trial plans to enroll 10 participants.